MAPT and Alzheimer disease: The above discussion and argument indicate that upregulated AEPs and AEP-mediated APP and tau cleavage not only initiate AD, but are also upstream signals of amyloid or tau toxicity and thereby worthy of being explored as preclinical biomarkers.